News

The expanded label now includes the addition of two thumb muscles: flexor pollicis longus and adductor pollicis; increasing the maximum dose from 360 to 400 units to teat

Paclical is the first water-soluble cancer drug with paclitaxel to receive a market authorization and the product is scheduled to be launched in the second half of 2015.

The company’s second clinical compound, CCX872 is an orally administered inhibitor of the chemokine receptor known as CCR2. Around 54 patients with non-resectable pancreatic cancer will be included

According to the data, ixekizumab was statistically superior to placebo in the treatment of patients with active PsA, as showed by the proportion of patients achieving an ACR

TetraLogic is focused on discovering and developing new small molecule therapeutics in oncology and infectious diseases. As part of the deal, the two firms will conduct an initial

Daiichi Sankyo received around 9% stake in Sun Pharma following the merger of Ranbaxy with the Indian pharmaceutical firm. Under the deal, Ranbaxy shareholders were to receive 0.8

In 2015, the two trials will be examining, RGN-259/GBT201, ReGenTree’s preservative-free eye drops. Each of these eye disorders was being targeted by RegeneRx before entering into the joint

The randomized, double-blind, multicenter, placebo-controlled (2:1) MS-SPI trial evaluated the efficacy and safety of MD1003, 300mg/day, in patients with progressive MS who have showed progression in the two

An ODD has been applied by the company for pediatric high grade gliomas (HGG), however the FDA granted an ODD for the broader indication of malignant glioma in